Kinnevik Results Presentation Deck

OUR USD 50 MILLION FOLLOW-ON INVESTMENT INTO SPRING HEALTH IN Q1 IS A PERFECT EXAMPLE OF USING 2023 TO DOUBLE DOWN IN OUR WINNERS ■ ■ Redoubling our commitment in one of our high- conviction, strong-performing businesses at a balanced USD 2.5bn valuation ■ ■ Significant Follow-On in Spring Health Supporting & Maximizing Impact of High-Conviction Businesses I USD 40m primary investment in a 71m round, corresponding to >10x our pro rata share USD 10m secondary purchase from an early-stage investor in need of liquidity Accreting ownership from 5 to 7% Spring has grown revenues by more than 4x since our 2021 investment on an NTM basis, and by more than 7x on an LTM basis The business is now funded to break-even with a path to reach cash flow profitability in 2024 through operating leverage Emerging as a new star healthcare investment behind Livongo, Cedar, Cityblock and VillageMD with significant growth opportunities ahead From Our 1st Investment to Today Select KPIs 4.3x Growth in NTM Revenue 2.7x Growth in Corporate Clients (69)% Change in EV/NTM Revenue 2.4x Growth in Covered Lives "Kinnevik has become our trusted partner and advisor for every part of our business. It's easy to take a long-term stance in a bull market, and Kinnevik has proven to us they are a wonderful partner no matter the macro environment. Kinnevik has stood with us for all our growth, as well as the occasional bump in the road that every startup faces. Everyone looks for a value-add investor, and there's no question that Kinnevik fits that profile." April Koh CEO and Co-Founder Spring Health has the potential and the momentum to become one of Kinnevik's most successful healthcare investments, and 2023 created an opportunity for us to lean in and commit more capital at a rebalanced valuation, providing the company fast access to capital and ability to focus singularly on continuing to capture the massive market opportunity KINNEVIK

View entire presentation